CN1209746A - 抑制肌腱膜纤维瘤病(硬纤维瘤)的方法 - Google Patents

抑制肌腱膜纤维瘤病(硬纤维瘤)的方法 Download PDF

Info

Publication number
CN1209746A
CN1209746A CN97191916A CN97191916A CN1209746A CN 1209746 A CN1209746 A CN 1209746A CN 97191916 A CN97191916 A CN 97191916A CN 97191916 A CN97191916 A CN 97191916A CN 1209746 A CN1209746 A CN 1209746A
Authority
CN
China
Prior art keywords
chemical compound
preparation
cell
acid
milligram
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN97191916A
Other languages
English (en)
Chinese (zh)
Inventor
M·L·布兰迪
F·托内利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9603148.9A external-priority patent/GB9603148D0/en
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CN1209746A publication Critical patent/CN1209746A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)
CN97191916A 1996-01-29 1997-01-27 抑制肌腱膜纤维瘤病(硬纤维瘤)的方法 Pending CN1209746A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US1077396P 1996-01-29 1996-01-29
US60/010,773 1996-01-29
GB9603148.9 1996-02-15
GBGB9603148.9A GB9603148D0 (en) 1996-02-15 1996-02-15 Methods of inhibiting musculoaponeurotic fibromatoses (desmoid tumors)

Publications (1)

Publication Number Publication Date
CN1209746A true CN1209746A (zh) 1999-03-03

Family

ID=26308707

Family Applications (1)

Application Number Title Priority Date Filing Date
CN97191916A Pending CN1209746A (zh) 1996-01-29 1997-01-27 抑制肌腱膜纤维瘤病(硬纤维瘤)的方法

Country Status (11)

Country Link
EP (1) EP0907361A4 (ja)
JP (1) JP2000503995A (ja)
KR (1) KR19990082055A (ja)
CN (1) CN1209746A (ja)
AU (1) AU707675B2 (ja)
CZ (1) CZ235398A3 (ja)
EA (1) EA199800678A1 (ja)
IL (1) IL125523A0 (ja)
NO (1) NO983452L (ja)
PL (1) PL328127A1 (ja)
WO (1) WO1997026878A1 (ja)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2135195C1 (ru) * 1998-12-17 1999-08-27 Овсюк Валерий Григорьевич Способ получения материала, содержащего клетки предстательной железы, материал, содержащий клетки предстательной железы, и способы лечения фиброматоза матки, хронического простатита и нарушений мужской половой функции методом трансплантации
AU781168B2 (en) * 2001-01-26 2005-05-12 Pfizer Products Inc. Method of treating certain cancers using an estrogen agonist/antagonist

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
US5552162A (en) * 1993-02-09 1996-09-03 Arch Development Corporation Method for improvement of scar size and appearance
HUT71237A (en) * 1993-10-15 1995-11-28 Lilly Co Eli Pharmaceutical compositions for treating resistant neoplasms containing 2-phenyl-3-aroil-benzotiophene derivatives and process for their preparation
US5457116A (en) * 1993-10-15 1995-10-10 Eli Lilly And Company Methods of inhibiting uterine fibrosis
US5574047A (en) * 1993-12-21 1996-11-12 Eli Lilly And Company Methods of inhibiting imperfect tissue repair

Also Published As

Publication number Publication date
WO1997026878A1 (en) 1997-07-31
EP0907361A4 (en) 2002-05-02
AU2124097A (en) 1997-08-20
NO983452D0 (no) 1998-07-27
CZ235398A3 (cs) 1999-02-17
KR19990082055A (ko) 1999-11-15
AU707675B2 (en) 1999-07-15
JP2000503995A (ja) 2000-04-04
PL328127A1 (en) 1999-01-18
EP0907361A1 (en) 1999-04-14
NO983452L (no) 1998-07-27
IL125523A0 (en) 1999-03-12
EA199800678A1 (ru) 1999-02-25

Similar Documents

Publication Publication Date Title
CN1049335C (zh) 苯并噻吩类化合物的制药用途
CN1043608C (zh) 关于苯并噻吩类的改进
US20050113307A1 (en) Methods of treating cancer and the pain associated therewith using endothelin antagonists
CN1173821A (zh) 抑制细胞－细胞粘连的方法
CN1058390C (zh) 苯并噻吩类化合物的用途
CN1108255A (zh) 抑制经期前综合征/晚黄体期焦虑疾病的症状的方法
CN1107156A (zh) 抑制子宫纤维变性的方法
CN1107706A (zh) 抑制皮脂溢和痤疮的方法
CN1107705A (zh) 提高绝经后妇女性欲的方法
CN1107332A (zh) 抑制绝经后妇女的中枢神经系统问题的方法
CN1107702A (zh) 抑制卵巢发育不全、青春发育延迟或性幼稚型的方法
CN1108099A (zh) 抑制性早熟的方法
CN1108100A (zh) 抑制乳房病症的方法
CN1108103A (zh) 抑制特纳综合征的方法
CN1278812A (zh) 用于治疗雌激素缺乏症的2－芳基－3－芳酰基苯并[b]噻吩
CN1169116A (zh) 抑制环境雌激素的方法
CN1209746A (zh) 抑制肌腱膜纤维瘤病(硬纤维瘤)的方法
EP1347751B1 (en) Methods of treating bone cancer and the pain associated therewith using endothelin antagonists
CZ106098A3 (cs) Použití benzothiofenu k přípravě farmaceutického prostředku k inhibici inhibitoru 1 plasminogenového aktivátoru
AU688112B2 (en) Methods of inhibiting endometrial cancer
CN1108101A (zh) 抑制男性不育症的方法
US5843964A (en) Methods of inhibiting endometrial mitoses
US5670523A (en) Methods of inhibiting musculoaponeurotic fibromatoses (desmoid tumors)
CN1177295A (zh) 抑制生长激素作用的方法
CN1193274A (zh) 钙离子通道拮抗剂

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1045588

Country of ref document: HK